Anebulo Pharmaceuticals (ANEB) Insider Trading & Ownership $1.26 -0.16 (-10.95%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.28 +0.02 (+1.59%) As of 02/21/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Anebulo Pharmaceuticals (NASDAQ:ANEB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage85.90%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$10.00 MNumber OfInsiders Selling(Last 12 Months)0 Get ANEB Insider Trade Alerts Want to know when executives and insiders are buying or selling Anebulo Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ANEB Insider Buying and Selling by Quarter Anebulo Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/23/2024Aron R EnglishDirectorBuy10,101,010$0.99$9,999,999.90 (Data available from 1/1/2013 forward) ANEB Insider Trading Activity - Frequently Asked Questions Who is on Anebulo Pharmaceuticals's Insider Roster? The list of insiders at Anebulo Pharmaceuticals includes Aron R English. Learn more on insiders at ANEB. What percentage of Anebulo Pharmaceuticals stock is owned by insiders? 85.90% of Anebulo Pharmaceuticals stock is owned by insiders. Learn more on ANEB's insider holdings. Which Anebulo Pharmaceuticals insiders have been buying company stock? The following insider purchased ANEB shares in the last 24 months: Aron R English ($9,999,999.90). How much insider buying is happening at Anebulo Pharmaceuticals? Insiders have purchased a total of 10,101,010 ANEB shares in the last 24 months for a total of $9,999,999.90 bought. Anebulo Pharmaceuticals Key ExecutivesDr. Joseph F. Lawler M.D. (Age 52)Ph.D., Founder & Chairman Compensation: $11kDr. Kenneth C. Cundy Ph.D. (Age 65)Chief Scientific Officer Compensation: $425.15kMr. Richard Anthony Cunningham (Age 53)CEO & Director Mr. Daniel V. George (Age 54)Principal Accounting Officer, Acting CFO & Secretary Mr. Scott L. AndersonHead of Investor Relations & Public Affairs More Insider Trading Tools from MarketBeat Related Companies CHRS Insider Transactions BMEA Insider Transactions BDTX Insider Transactions CABA Insider Transactions TSVT Insider Transactions KYTX Insider Transactions SGMT Insider Transactions RENB Insider Transactions CRBU Insider Transactions IZTC Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:ANEB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
